'Looking ahead to the rest of 2023, we expect results from our multiple dose cohort Phase 1 study of RLYB212, our anti-HPA-1a monoclonal antibody product candidate for the prevention of fetal and neonatal alloimmune thrombocytopenia, in the fourth quarter of 2023. I look forward to continuing my close partnership with Martin in his new role as Executive Chairman, as we, together with our Board of Directors and our employees, continue to execute Rallybio's mission and strategy,' said Dr. I am excited to build on our successes, advance our clinical programs, and work tirelessly towards delivering new product candidates from our discovery collaborations. 'It is a great privilege to lead Rallybio and our experienced and talented team on our mission to establish the Company as a leader in the development of transformative medicines for underserved rare diseases. Mackay will remain a full-time employee and continue to be actively involved with the Company, with a particular focus on company strategy, investor relations and related activities. He will succeed Martin Mackay, Ph.D., Chief Executive Officer, Chairman of the Board, and Co-Founder, who will assume the role of Executive Chairman. The Company does not expect to hire a replacement for Dr. Uden will remain President and will also be appointed to Rallybio's Board of Directors. “The GIFTED Leadership team and colleagues work with a hybrid of technology and traditional solution-based strategy that benefits clients and clinicians.NEW HAVEN - Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Stephen Uden, M.D., Rallybio's President, Chief Operating Officer and Co-Founder has been appointed to the role of Chief Executive Officer, effective August 1, 2023.ĭr. “Joining GIFTED at a time when the staffing industry continues to evolve at a rapid pace is an exciting challenge,” said Turner. “Our primary differentiator in our space is the prioritization of human connection and Turner’s skill and vision align with this priority and vision.” “Turner possesses servant leadership qualities and aligns with GIFTED’s organizational vision and values, making him a strong fit for our corporate culture and team,” said Dennis Ducham, GIFTED CEO. Most recently, Turner was the COO for SThree, a STEM staffing company. In 2014, he joined Kelly’s Outsourcing Division where he became the Chief Recruiting Officer for a $1.2B Science, Education, and Technology Division. He started his career in staffing as a recruiter at Kforce and over his 13-year tenure he led the initiative to build a National Recruiting Center that grew to more than 300 recruiters. Turner comes with an extensive background in staffing and recruitment, positioning him well to assume leadership over operations. Turner, with 20 years of experience in the staffing industry, is a Virginia Military Institute graduate and served our country as an Infantry Officer in the Marine Corps. GIFTED Healthcare is pleased to announce the appointment of Dan Turner as Chief Operations Officer starting January 2023.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |